재조합 알부민 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of recombinant albumin Market

The global recombinant albumin market was valued at USD 150.67 billion in 2025 and is projected to grow to USD 159.26 billion in 2026, eventually reaching USD 260.04 billion by 2034, exhibiting a CAGR of 6.05% during the forecast period. Asia Pacific dominated the market in 2025 with a 49.28% share, driven by the increasing prevalence of chronic kidney diseases, rising healthcare expenditure, and strategic collaborations between major market players. Recombinant albumin, a key plasma protein, serves as a safer and scalable alternative to human-derived albumin, providing applications in drug delivery, diagnostics, and as a cell culture supplement.

Key players such as InVitria, FUJIFILM Wako Pure Chemical Corporation, and Sartorius AG are expanding their geographic presence and investing in research and development (R&D) to strengthen their market dominance. Strategic collaborations and innovative product launches further support the growth of the market, enabling large-scale production of virus-free recombinant albumin suitable for advanced therapeutics.

Market Dynamics

Drivers: The increasing application of recombinant albumin in cell and gene therapy is a major growth driver. It stabilizes sensitive therapeutic molecules, improves cell viability, and protects against aggregation or degradation. For instance, Albumedix collaborated with CGT Catapult in February 2021 to explore albumin-based solutions for advanced therapy applications, demonstrating its critical role in this sector.

Restraints: Supply limitations pose a challenge for market expansion. Manufacturing recombinant albumin requires advanced expression systems, GMP compliance, and costly purification technologies. These factors lead to low yields and high production costs. For example, Mitsubishi Chemical Group Corporation terminated its recombinant human serum production in July 2022 due to supply instability.

Opportunities: Research and development in advanced drug delivery systems, such as nanoparticle albumin-bound (nab) technology, is creating lucrative opportunities. Nab-technology improves delivery of low-solubility and high-toxicity drugs with fewer side effects. For instance, Sandoz launched a generic paclitaxel albumin-bound formulation in October 2024 for metastatic breast cancer therapy.

Challenges: The high cost of recombinant albumin limits adoption. Products like Optibumin 20 are priced at USD 1,660 for 100 mL, reflecting the complex production and purification processes involved, which hampers widespread usage.

Market Trends

An important trend is the expansion of manufacturing capacity by key players. Increasing demand for GMP-grade recombinant albumin in cell and gene therapies has driven investments in production scale-up. For example, Yantai Projiji Pharmaceutical Technology Co., Ltd. announced a recombinant albumin expansion project in March 2025, demonstrating market growth momentum.

Segmentation Analysis

By Dosage Form: The solution segment dominates due to lower contamination risk, ready-to-use formulations, and consistency. InVitria launched Optibumin 25 solution in February 2025, offering a safe alternative for biomanufacturing in cell and gene therapy.

By Application: The therapeutic segment captured the largest share in 2024. Recombinant albumin is essential as an excipient and active component in therapies due to its biocompatibility and stability. For example, Albumedix collaborated with Heartseed in March 2023 to supply Recombumin for cardiac remuscularization cell therapy.

By End-User: Pharmaceutical and biotechnology industries dominate as end-users, leveraging strategic collaborations, expanded manufacturing, and commercialization partnerships. In June 2024, Dyadic International partnered with PHB to commercialize recombinant albumin, with launches expected in 2025.

Regional Outlook

Asia Pacific: Dominated the market in 2025 with USD 74.25 billion, driven by chronic disease prevalence, rising healthcare expenditure, and strategic collaborations.

North America: Expected steady growth at a 5.08% CAGR, with USD 44.5 million in 2025, driven by a strong biopharma R&D base and GMP-compliant manufacturing facilities.

Europe: Projected growth at 4.02% CAGR, reaching USD 24.0 million in 2025, supported by advanced research and demand in therapeutic applications.

Latin America & Middle East & Africa: Moderate growth is expected, with Latin America reaching USD 6.1 million in 2025, aided by regenerative medicine adoption and increasing recombinant albumin usage.

Competitive Landscape

The market is concentrated, dominated by Sartorius AG, FUJIFILM Wako Pure Chemical Corporation, and InVitria. Their strong global presence, product portfolios, and strategic collaborations reinforce market leadership. Other key players include Thermo Fisher Scientific, Merck KGaA, and Orion Corporation. Notable developments include:

• August 2023: Dyadic International announced positive testing results for animal-free recombinant albumin.
• August 2022: Sartorius AG acquired Albumedix for USD 449.13 million.
• July 2025: Wuhan Healthgen Biotechnology received approval for rice-derived recombinant human albumin injection in China.

Conclusion

The global recombinant albumin market is expected to grow from USD 150.67 billion in 2025 to USD 159.26 billion in 2026, reaching USD 260.04 billion by 2034 at a CAGR of 6.05%. Growth is driven by its widespread applications in therapeutics, cell and gene therapy, and advanced biologics manufacturing. Asia Pacific leads the market due to rising chronic disease prevalence and strategic collaborations. Despite challenges like high costs and supply limitations, R&D investments, manufacturing expansion, and drug delivery innovations are anticipated to drive significant market growth, making it a lucrative opportunity for major players and new entrants alike.

Segmentation By Dosage Form

• Powder
• Solution

By Application

• Therapeutics
• Diagnostics
• Research

By End User

• Hospital & Clinics
• Pharmaceutical & Biotechnology Industry
• Research Institutes

By Geography

• North America (By Dosage Form, Application, End User, and Country)
  • U.S.
  • Canada
• Europe (By Dosage Form, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Dosage Form, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Dosage Form, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Dosage Form, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Technological Advancements in the Market
• 4.2. Regulatory Scenario by Key Countries/ Region, 2025
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.1.1. Powder
  • 5.1.2. Solutions
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Therapeutics
  • 5.2.2. Diagnostics
  • 5.2.3. Research
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospital & Clinics
  • 5.3.2. Pharmaceutical & Biotechnology Industry
  • 5.3.3. Research Institutes
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.1.1. Powder
  • 6.1.2. Solution
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Therapeutics
  • 6.2.2. Diagnostics
  • 6.2.3. Research
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospital & Clinics
  • 6.3.2. Pharmaceutical & Biotechnology Industry
  • 6.3.3. Research Institutes
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.1.1. Powder
  • 7.1.2. Solution
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Therapeutics
  • 7.2.2. Diagnostics
  • 7.2.3. Research
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospital & Clinics
  • 7.3.2. Pharmaceutical & Biotechnology Industry
  • 7.3.3. Research Institutes
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.1.1. Powder
  • 8.1.2. Solution
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Therapeutics
  • 8.2.2. Diagnostics
  • 8.2.3. Research
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospital & Clinics
  • 8.3.2. Pharmaceutical & Biotechnology Industry
  • 8.3.3. Research Institutes
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.1.1. Powder
  • 9.1.2. Solution
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Therapeutics
  • 9.2.2. Diagnostics
  • 9.2.3. Research
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospital & Clinics
  • 9.3.2. Pharmaceutical & Biotechnology Industry
  • 9.3.3. Research Institutes
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Dosage Form
  • 10.1.1. Powder
  • 10.1.2. Solution
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Therapeutics
  • 10.2.2. Diagnostics
  • 10.2.3. Research
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospital & Clinics
  • 10.3.2. Pharmaceutical & Biotechnology Industry
  • 10.3.3. Research Institutes
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. InVitria
  • 11.2.2. FUJIFILM Wako Pure Chemical Corporation
  • 11.2.3. Orion Corporation
  • 11.2.4. Sartorius AG
  • 11.2.5. Thermo Fisher Scientific Inc.
  • 11.2.6. Merck KGaA